^
    Back
    Association details:
    Biomarker:EML4-ALK L1196M
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

    Excerpt:
    ALK Mutations Confer Resistance to Crizotinib.
    DOI:
    10.1097/JTO.0b013e318283dcc0
    Trial ID:
    PROFILE 1001